PLA2G2C and depressive symptom measurement: Following the analysis of the metabolic pathways, seven genes including ALOX5, LTA4H, CYP4Y, PLA2G2C, AKR1C1, AKR1D1 and CYP17A1 were employed to elucidate further the potential mechanisms underlying CS treatment of depression.